Results of a naturalistic study of treatment options: Switching atypical antipsychotic drugs or augmenting with valproate

Clinical Therapeutics

Volumn 26, Issue 6, 2004, Pages 905-914

  Cramer, Joyce A ^a   Sernyak, Michael ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vet Aff Connecticut Hlthcare S   (United States)

Author keywords

antipsychotic; divalproex; olanzapine; quetiapine; risperidone; valproate

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PSYCHOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 3242719764     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90134-8     Document Type: Article

References (27)

1. Leslie D.L., Rosenbeck R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system. Med Care. 39:2001;923-933
2. Lehman A.F., Steinwachs D.M. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 24:1998;1-10
3. Zyprexa. 2004;Eli Lilly and Company, Indianapolis, Ind. [package insert]
4. Seroquel. 2004;AstraZeneca Pharmaceuticals LP, Wilmington, Del. [package insert]
5. Risperdal. 2003;Janssen Pharmaceutica Products, LP, Titusville, NJ. [package insert]
6. Leslie D.L., Rosenheck R.A. From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications. Am J Psychiatry. 159:2002;1534-1540
7. Menzin J., Boulanger L., Friedman M., et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 54:2003;719-723
8. Tapp A., Wood A.E., Secrest L., et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 54:2003;55-59
9. Zhao Z., Tunis S.L., Lage M.J. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest. 22:2002;741-749
10. Citrome L., Levine J., Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 51:2000;634-638
11. Mattson R.H., Cramer J.A., Collins J.F. Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 327:1992;765-771
12. Freitag F.G., Collins S.D., Carlson H.A., et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 58:2002;1652-1659
13. Casey D.E., Daniel D.G., Wassef A.A., et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 28:2003;182-192
14. Wassef A.A., Dott S.G., Harris A., et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol. 20:2000;357-361
15. Muller-Oerlinghausen B., Retzow A., Henn F.A., et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol. 20:2000;195-203
16. Pub L No. 104-191.
17. Vanelli M., Burstein P., Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv. 52:2001;1248-1250
18. Sernyak M.J., Leslie D.L., Alarcon R.D., et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 159:2002;561-566
19. Sernyak M.J., Gulanski B., Leslie D.L., Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry. 64:2003;605-608
20. Zito J.M. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am. 21:1998;181-202
21. Post R.M., Ketter T.A., Pazzaglia P.J., et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 11:1996;153-180
22. Wassef A.A., Dott S.G., Harris A., et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol. 19:1999;222-232
23. Krystal J.H., Sanacora G., Blumberg H., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 7:(Suppl 1):2002;S71-S80
24. Buchanan R.W., Kreyenbuhl J., Zito J.M., et al. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry. 159:2002;1035-1043
25. Sachs G.S., Grossman F., Ghaemi S.N., et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 159:2002;1146-1154
26. Sajatovic M., Brescan D.W., Perez D.E., et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry. 62:2001;728-732
27. Bowden C.L., Brugger A.M., Swann A.C., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. [published correction appears in JAMA. 1994; 271: 1830] JAMA. 271:1994;918-924